Erratum: Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer (Journal of Clinical Oncology (2016) 34 (4079-4085) DOI: 10.1200/JCO.2016.68.4639);Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 34, Issue 34, 2016, Pages 4079-4085

  Gadgeel, Shirish M ^a   Shaw, Alice T ^b   Govindan, Ramaswamy ^d   Gandhi, Leena ^c   Socinski, Mark A ^e   Camidge, D Ross ^f   De Petris, Luigi ⁱ   Kim, Dong Wan ^j   Chiappori, Alberto ^g   Moro Sibilot, Denis L ^l   Duruisseaux, Michael ^m   Crino, Lucio ^o   De Pas, Tommaso ^p   Dansin, Eric ⁿ   Tessmer, Antje ^q   Yang, James Chih Hsin ^r   Han, Ji Youn ^k   Bordogna, Walter ^s   Golding, Sophie ^s   Zeaiter, Ali ^s   Ou, Sai Hong Ignatius ^h   more..

^a WAYNE STATE UNIVERSITY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^g H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ KAROLINSKA INSTITUTE   (Sweden)

^j Seoul National University Hospital   (South Korea)

^k National Cancer Center   (South Korea)

^l Service de Pneumologie   (France)

^m GRENOBLE UNIVERSITY HOSPITAL   (France)

ⁿ CENTRE OSCAR LAMBRET   (France)

^o SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^p EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^q Evangelische Lungenklinik Berlin   (Germany)

^r NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^s F HOFFMANN LA ROCHE LTD   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALECTINIB; CRIZOTINIB; CARBAZOLE DERIVATIVE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; BRAIN RADIATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; PATIENT HISTORY OF RADIOTHERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; BIOASSAY; CARCINOMA, NON-SMALL-CELL LUNG; CENTRAL NERVOUS SYSTEM NEOPLASMS; CLINICAL TRIAL; LUNG NEOPLASMS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; SECONDARY; TREATMENT OUTCOME;

ADULT; AGED; CARBAZOLES; CARCINOMA, NON-SMALL-CELL LUNG; CENTRAL NERVOUS SYSTEM NEOPLASMS; ENDPOINT DETERMINATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; TREATMENT OUTCOME;

EID: 84995877117     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2017.73.5142     Document Type: Erratum

References (28)

1. Camidge DR, Bang YJ, Kwak EL, et al: Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study. Lancet Oncol 13:1011-1019, 2012
2. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines for non-small-cell lung cancer. V6.2015. http://www.nccn.org/professionals/physician-gls/pdf/nscl.pdf
3. Lovly CM, Shaw AT: Molecular pathways: Resistance to kinase inhibitors and implications for therapeutic strategies. Clin Cancer Res 20:2249-2256, 2014
4. Ou SH, Jänne PA, Bartlett CH, et al: Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol 25:415-422, 2014
5. Niemiec M, Głogowski M, Tyc-Szczepaniak D, et al: Characteristics of long-term survivors of brain metastases from lung cancer. Rep Pract Oncol Radiother 16:49-53, 2011
6. Costa DB, Shaw AT, Ou SH, et al: Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol 33:1881-1888, 2015
7. Khozin S, Blumenthal GM, Zhang L, et al: FDA approval: Ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. Clin Cancer Res 21:2436-2439, 2015
8. Ou SH, Ahn JS, De Petris L, et al: Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: A phase II global study. J Clin Oncol 34:661-668, 2016
9. Seto T, Kiura K, Nishio M, et al: CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): A single-arm, open-label, phase 1-2 study. Lancet Oncol 14:590-598, 2013
10. Ohe Y, Nishio M, Kiura K, et al: A phase I/II study with a CNS-penetrant, selective ALK inhibitor alectinib in ALK-rearranged non-small cell lung cancer (ALK+ NSCLC) patients (pts): Updates on progression free survival (PFS) and safety results from AF-001JP. J Clin Oncol 33, 2015 (suppl; abstr 8061)
11. McKeage K: Alectinib: A review of its use in advanced ALK-rearranged non-small cell lung cancer. Drugs 75:75-82, 2015
12. Shaw AT, Gandhi L, Gadgeel S, et al: Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: A single-group, multicentre, phase 2 trial. Lancet Oncol 17:234-242, 2016
13. Gadgeel SM, Gandhi L, Riely GJ, et al: Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): Results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 15:1119-1128, 2014
14. Solomon BJ, Mok T, Kim DW, et al: First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371:2167-2177, 2014
15. Costa DB, Kobayashi S, Pandya SS, et al: CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 29:e443-e445, 2011
16. Barlesi F, Dingemans A-MC, Ou S-HI, et al: Updated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK+ non-small-cell lung cancer (NSCLC). Eur J Cancer 51, 2015 (suppl 3; abstr 3101)
17. Kodama T, Hasegawa M, Takanashi K, et al: Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol 74:1023-1028, 2014
18. Horiike A, Hida T, Nakagawa K, et al: Antitumor activity of alectinib against brain metastases from ALK rearranged NSCLC: Subset analysis of JP28927. Jpn J Lung Cancer 54:O-14, 2014 (abstr)
19. Gainor JF, Sherman CA, Willoughby K, et al: Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol 10:232-236, 2015
20. Ou SH, Sommers KR, Azada MC, et al: Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis. Oncologist 20:224-226, 2015
21. Shaw AT, Mehra R, Tan DSW, et al: Evaluation of ceritinib-treated patients with anaplastic lymphoma kinase rearranged (ALK+) non-small cell lung cancer (NSCLC) and brain metastases in the ASCEND-1 study. Ann Oncol 25:iv426-iv470, 2014 (suppl 4)
22. Misra A, Ganesh S, Shahiwala A, et al: Drug delivery to the central nervous system: A review. J Pharm Pharm Sci 6:252-273, 2003
23. Kort A, Sparidans RW, Wagenaar E, et al: Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2). Pharmacol Res 102:200-207, 2015
24. Bergqvist M, Brattström D, Bennmarker H, et al: Irradiation of brain metastases from lung cancer: A retrospective study. Lung Cancer 20:57-63, 1998
25. Komatsu T, Kunieda E, Oizumi Y, et al: Clinical characteristics of brain metastases from lung cancer according to histological type: Pretreatment evaluation and survival following whole-brain radiotherapy. Mol Clin Oncol 1:692-698, 2013
26. Brown PD, Asher AL, Ballman KV, et al: NCCTG N0574 (Alliance): A phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases. J Clin Oncol 33, 2015 (suppl; abstr LBA4)
27. Yamamoto M, Serizawa T, Shuto T, et al: Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): A multi-institutional prospective observational study. Lancet Oncol 15:387-395, 2014
28. Nokihara H, Hida T, Kondo M, et al: Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study. J Clin Oncol 34, 2016 (suppl; abstr 9008)